Lobello et al. found that silencing FTH in ovarian cancer changes miRNA levels (increasing miR-146a and miR-150 while decreasing miR-125b), affecting cell survival, drug resistance, and migration [194]. The gene discussed is FTH1; the disease is ovarian cancer.